HLX07 clinical trials
Also written HLX07.
How each study uses HLX07 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the HLX07 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2022 (7)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2022 | 7 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 17 · Other 1
Shanghai Henlius Biotech (16) · Henlix, Inc (1) · Wuhan Union Hospital, China (1)
Often tested with
Tested in the same studies.
Serplulimab (5) · Anti-PD-L1 Antibody-drug Conjugate HLX43 (3) · Modified FOLFOX6 Regimen (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test HLX07.
- Jul 2027A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal CancerPhase 1/2 · Shanghai Henlius Biotech
Studies
Open first, then newest update. How each study uses HLX07 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 18
- A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung CancerRecruitingPhase 2/3Shanghai Henlius BiotechNCT07459751Written as HLX43+HLX07
- A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaRecruitingPhase 2Shanghai Henlius BiotechNCT06857279Written as HLX43 DOSE 2 + HLX10 + HLX07
- A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal CancerNot yet recruitingPhase 1/2Shanghai Henlius BiotechNCT07358585Written as HLX43 dose 1 + HLX07
- A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung CancerNot yet recruitingPhase 2/3Shanghai Henlius BiotechNCT07318883Written as HLX07
- Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARCRecruitingPhase 2Wuhan Union Hospital, ChinaNCT06542588Written as HLX07(anti EGFR antibody) and Serplulimab(anti PD-1 antibody)
- A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCCRecruitingPhase 2Shanghai Henlius BiotechNCT05221658Written as HLX07+HLX10+ Cisplatin+5-FU
- Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRCNot yet recruitingPhase 2Shanghai Henlius BiotechNCT05239650Written as HLX07
- Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPCActive, not recruitingPhase 2Shanghai Henlius BiotechNCT05513573Written as HLX07
- Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck TumorsActive, not recruitingPhase 2Shanghai Henlius BiotechNCT04297995Written as HLX07
- The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors.CompletedPhase 1/2Shanghai Henlius BiotechNCT03577704Written as HLX07+Gemcitabine+Cisplatin
- A Study to Evaluate the Efficacy and Safety of HLX07 in nsqNSCLC Patients With High EGFR ExpressionStatus unknownPhase 2Shanghai Henlius BiotechNCT05215925Written as HLX07+carboplatin+pemetrexed
- The Efficacy and Safety of HLX07 in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)Status unknownPhase 2Shanghai Henlius BiotechNCT05238363Written as HLX07
- A Study of HLX07 + HLX10 With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLCStatus unknownPhase 2Shanghai Henlius BiotechNCT04976647Written as HLX10+HLX07+chemo
- HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid TumorsStatus unknownPhase 1Shanghai Henlius BiotechNCT05360368Written as HLX07
- A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung CancerStatus unknownPhase 2Shanghai Henlius BiotechNCT05354700Written as HLX07
- HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular CarcinomaStatus unknownPhase 2Shanghai Henlius BiotechNCT05290220Written as HLX07
- HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric CancerStatus unknownPhase 2Shanghai Henlius BiotechNCT05246982Written as HLX07+HLX10+oxaliplatin+capecitabine
- An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid CancersCompletedPhase 1Henlix, IncNCT02648490Written as HLX07